Scientific Publications
Salmonella intracellular adaptation is key to understand cephalosporin treatment relapse.
EBioMedicine, 56, 102802
Due to the emergence of resistance to chloramphenicol in the 1990’s and more recently to fluoroquinolones, third generation cephalosporins (b-lactam antibiotics), along with azithromycin, are now the treatments of choice for enteric fever2. Resistance to cephalosporins is currently relatively low for S. Typhi and S. Paratyphi A, the causative agents of enteric fever, but as much as 17% of cases treated with this class of antibiotic end with relapse3. Relapse not only increases morbidity and mortality to enteric fever, but may also contribute to the emergence of resistance to this important first choice drug. Indeed, the first reports of resistance to third generation cephalosporins in addition to multi-drug resistance affecting other drug choices, a profile called extensively drug resistant (XDR), was reported in outbreaks in India and Pakistan in 20164. The emergence of the XDR profile is a serious escalation in the potential lethality of enteric fever in the coming years.
EBioMedicine, 56, 102802
View Publication
